Exicure (NASDAQ:XCUR) Shares Down 0.8% – Should You Sell?

Exicure, Inc. (NASDAQ:XCUR) was down 0.8% on Thursday. The company traded as low as $1.2150 and last traded at $1.23. 22,873 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 37,063 shares. The stock had previously closed at $1.24.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Exicure in a report on Tuesday, September 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Exicure has an average rating of “Sell”.

Exicure Price Performance

The firm has a market capitalization of $7.93 million, a PE ratio of -0.92 and a beta of 3.63. The company’s fifty day simple moving average is $1.41 and its 200-day simple moving average is $2.58.

Exicure (NASDAQ:XCUR) last released its earnings results on Friday, August 14th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($18.60) by $18.42.

About Exicure

Exicure, Inc was a biotechnology company focused on developing therapeutics based on its spherical nucleic acid (SNA) technology. The company’s platform was designed to deliver nucleic acids into cells and tissues, with the goal of regulating disease-related genes and proteins.

Exicure’s research programs addressed conditions in dermatology, immunology and other therapeutic areas. Its development portfolio included candidates such as AST-005, an SNA-based therapy investigated for psoriasis, along with programs targeting inflammatory and genetic diseases.